NCT01838720

Brief Summary

To evaluate the feasibility and efficiency of zero ischemia laparoscopic radio frequency ablation assisted enucleation of T1a renal cell carcinoma in comparison with the conventional laparoscopic partial nephrectomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2013

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

April 14, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 24, 2013

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
Last Updated

August 13, 2014

Status Verified

August 1, 2014

Enrollment Period

1.5 years

First QC Date

April 14, 2013

Last Update Submit

August 12, 2014

Conditions

Keywords

renal cell carcinomaischemiaradio frequency ablation

Outcome Measures

Primary Outcomes (1)

  • the absolute change in glomerular filtration rate (GFR) of the affected kidney

    12 months minus baseline

    baseline and 12 months

Secondary Outcomes (10)

  • estimated GFR (eGFR)

    12 months

  • changes in GFR of total kidneys by renal scintigraphyby

    baseline and 12 months

  • blood loss

    during surgery

  • surgical margin

    postoperative

  • postoperative complications

    12 months

  • +5 more secondary outcomes

Study Arms (2)

zero ischemia laparoscopic RFA assisted TE

EXPERIMENTAL

RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.

Procedure: zero ischemia laparoscopic RFA assisted TE

conventional laparoscopic partial nephrectomy

ACTIVE COMPARATOR

Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.

Procedure: ischemia

Interventions

Also known as: zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation
zero ischemia laparoscopic RFA assisted TE
ischemiaPROCEDURE

conventional laparoscopic partial nephrectomy

Also known as: renal artery will be clamped during surgery.
conventional laparoscopic partial nephrectomy

Eligibility Criteria

Age15 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients with sporadic, unilateral, newly diagnosed T1a presumed renal cell carcinoma
  • patients with normal contralateral renal function (differential renal function of \>40% as determined by radionuclide scintigraphy)
  • patients agreeable to participate in this long-term follow-up study

You may not qualify if:

  • patients' aged \>80 years
  • patients with other renal diseases
  • patients not able to tolerate the laparoscopic procedure
  • patients with previous renal surgery or history of any inflammatory conditions of the operative kidney
  • patients with the renal tumor close to the calyces

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

RenJi Hospital

Shanghai, Shanghai Municipality, 200127, China

RECRUITING

Related Publications (1)

  • Huang J, Zhang J, Wang Y, Kong W, Xue W, Liu D, Chen Y, Huang Y. Comparing Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Tumor Enucleation and Laparoscopic Partial Nephrectomy for Clinical T1a Renal Tumor: A Randomized Clinical Trial. J Urol. 2016 Jun;195(6):1677-83. doi: 10.1016/j.juro.2015.12.115. Epub 2016 Feb 22.

MeSH Terms

Conditions

Carcinoma, Renal CellIschemia

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Yiran Huang, M.D.

    RenJi Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yiran Huang, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 14, 2013

First Posted

April 24, 2013

Study Start

April 1, 2013

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

August 13, 2014

Record last verified: 2014-08

Locations